Skip to main content

Wet AMD — Deal Benchmarks & Valuation

Median Upfront
$768M
Range: $423M - $1.1B
Total Deal Value
$3.6B
Range: $2.4B - $4.9B
Royalty Rate
10.2% - 20.4%
Tiered up to 24.4%
Dev Milestones
$569M
Range: $385M - $756M

Market Analysis

Wet AMD is one of the most actively transacted indications in ophthalmology licensing. Phase 2 deals for wet amd carry a median total deal value of $3.6B, with upfront payments ranging from $423M to $1.1B. The recommended deal structure allocates approximately 21% to upfront payments and 79% to milestones.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

or
Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What are typical deal terms for wet amd licensing?
Phase 2 wet amd licensing deals average $768M in upfront payments with $3.6B total deal value. The 21/79 upfront/milestone split reflects the risk profile at this clinical stage.
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

or
Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating